Read by QxMD icon Read

Leukemia & Lymphoma

Jorne Lionel Biccler, Tarec Christoffer El-Galaly, Martin Bøgsted, Judit Jørgensen, Peter de Nully Brown, Christian Bjørn Poulsen, Jørn Starklint, Maja Bech Juul, Jacob Haaber Christensen, Pär Josefsson, Andriette Dessau, Lasse Hjort Jakobsen
No abstract text is available yet for this article.
November 14, 2018: Leukemia & Lymphoma
Ayalew Tefferi, Animesh Pardanani
No abstract text is available yet for this article.
November 14, 2018: Leukemia & Lymphoma
Nagendra K Chaturvedi, Nathan D Hatch, Garrett L Sutton, Matthew Kling, Julie M Vose, Shantaram S Joshi
Mantle cell lymphoma (MCL) represents an aggressive B-cell lymphoma with frequent relapse and poor survival. Recently, dysregulated histone-deacetylases (HDACs) and cell cycle CDK-Rb pathway have been shown to be commonly associated with MCL pathogenesis, and are considered promising targets for relapsed-lymphoma therapy. Therefore, we investigated the single agents and combination efficacy of HDACs inhibitor Vorinostat, CDK4/6 dual-inhibitor Palbociclib on MCL cell growth/survival and underlying molecular mechanism(s) using MCL cell lines including therapy-resistant MCL cell lines...
November 14, 2018: Leukemia & Lymphoma
Muhammad Husnain, Nicholas Mackrides, Francisco Vega, Manuel Paez-Escamilla, Arnold M Markoe, J William Harbour, Izidore S Lossos
No abstract text is available yet for this article.
November 14, 2018: Leukemia & Lymphoma
Panagiotis T Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, Vassiliki Pappa, Athanasios Galanopoulos, Dimitrios Gogos, Stamatios Karakatsanis, Helen Papadaki, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sotirios Papageorgiou, Sosana Delimpasis, Maria Papaioannou, Menelaos Papoutselis, Alexandra Kourakli, Dimitrios Tsokanas, Achilles Anagnostopoulos, Christos K Kontos, Panayiotis Panayiotidis, Nora-Athina Viniou
Hypomethylating agents are widely used in chronic myelomonocytic leukemia (CMML). We analyzed the characteristics of 88 patients with CMML homogeneously treated with 5-azacytidine (Hellenic 5-Azacytidine Registry). The overall response rate was 48.9% and the median overall survival (OS) 29.7 months. Out of the seven most widely used prognostic scoring systems for CMML, the Dusseldorf score (DUSS) showed the best prognostic capability (HR, 2.27; p < .001). Forty-one (48.8%) patients progressed to acute myeloid leukemia (AML) after a median time of 15...
November 14, 2018: Leukemia & Lymphoma
Liya Ma, Yingwan Luo, Lingxu Jiang, Dan Shen, Jianhu Li, Weilai Xu, Chen Mei, Xinping Zhou, Yanlin Ren, Li Ye, Chenxi Lu, Jin Jie, Hongyan Tong
According to 2008 WHO classification RARS is regarded as less than 5% blasts and more than 15% ring sideroblasts in the bone marrow. In 2016 WHO classification MDS-RS is revised as more than 15% ring sideroblasts or more than 5% ring sideroblasts in the presence of the SF3B1 mutation. In our study, we classified intracellular iron in bone marrow into four types according to the size and quantity of iron granules. We found that there was a significant difference between SF3B1-mutant and SF3B1-wild-type MDS patients in intracellular iron III, intracellular iron IV and ring sideroblasts...
November 9, 2018: Leukemia & Lymphoma
Jacob D Soumerai, Ai Ni, Guan Xing, Julie Huang, Richard R Furman, Jeffrey Jones, Jeffrey P Sharman, Michael Hallek, Adeboye H Adewoye, Ronald Dubowy, Lyndah Dreiling, Andrew D Zelenetz
The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3Kδ inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p < .0001; C-statistic 0...
November 8, 2018: Leukemia & Lymphoma
Guru Subramanian Guru Murthy, Satish Kumar Pondaiah, Sameem Abedin, Ehab Atallah
T-cell acute lymphoblastic leukemia (T-ALL) is a curable malignancy in the pediatric population. However, population-level data on its incidence and outcomes among adults is sparse. Using SEER database, we identified 1141 patients aged ≥20 years with pathologically confirmed T-ALL diagnosed between the years 2001 and 2014 and actively followed. Incidence of T-ALL was 0.13 cases/100,000 population with significant variations by age, gender, race, and period. The 5-year overall survival (OS) declined significantly with increasing age (age <40, 51...
November 8, 2018: Leukemia & Lymphoma
Filippo Pinto E Vairo, Alejandro Ferrer, Elizabeth Cathcart-Rake, Rebecca L King, Matthew T Howard, David S Viswanatha, Eric W Klee, Abhishek A Mangaonkar, Mrinal M Patnaik
No abstract text is available yet for this article.
November 8, 2018: Leukemia & Lymphoma
Chadi Nabhan, Siddhesh Kamat, Jonathan Karl Kish
Treatment options for patients with acute myeloid leukemia (AML), who are unfit for induction chemotherapy are unsatisfactory. Overall survival (OS) superiority has not been demonstrated in randomized controlled trials (RCT) in this population, challenging the value of available therapies. We sought to assess the relative value of approved therapies using value-assessment tools. Clinical, safety, quality-of-life (QOL), supportive care, and resource utilization outcomes data were abstracted from RCTs and examined using value-assessment frameworks...
November 8, 2018: Leukemia & Lymphoma
Meaghan Wall, Piers Blombery
No abstract text is available yet for this article.
November 8, 2018: Leukemia & Lymphoma
Cecilia M Rodriguez, Claudio Bussi, Daniela S Arroyo, Dario Sastre, Viviana Heller, Carmen Stanganelli, Irma Slavutsky, Pablo Iribarren
No abstract text is available yet for this article.
November 8, 2018: Leukemia & Lymphoma
Hongbo Yang, Hao Zhao, Xufei Huang, Xinxin Cao, Daobin Zhou, Jian Li
Hypothyroidism is the most common endocrine disorder in POEMS syndrome. In this single-center prospective study, 36 patients with newly diagnosed POEMS syndrome were treated with lenalidomide (10 mg daily for 21 days) and dexamethasone (40mg once per week) for 12 cycles. Hypothyroidism was demonstrated in 58.5% (24/41) at baseline, including 25% (6/24) of clinical hypothyroidism and 75% (18/24) of subclinical hypothyroidism. After 12-month treatment, the percentages of clinical hypothyroidism and subclinical hypothyroidism had decreased 11...
November 8, 2018: Leukemia & Lymphoma
Shandong Tao, Chunling Wang, Yue Chen, Yuan Deng, Lixiao Song, Yuyue Shi, Lanlan Ling, Banghe Ding, Zhengmei He, Liang Yu
The specific prognostic factors and the long-term effects of different treatment options in APL remain unclear. In this retrospective study, 70 APL patients were treated with ATRA + DNR/DA or ATRA + ATO regimens for induction therapy and DA or ATRA + ATO for consolidation and maintenance therapy. The prognostic factors and treatment effects on outcome were analyzed. Results showed that the 5-year OS in low-intermediate risk and high risk groups were 95.63% and 100%, and the 5-year RFS were 95.34% and 100%, respectively, the early mortality rate was 4...
November 8, 2018: Leukemia & Lymphoma
Katja Weisel, Pieter Sonneveld, Andrew Spencer, Meral Beksac, Maria Rizzo, Yingxin Xu, Kyle Fahrbach, Maren Gaudig, Mary Slavcev, Lindsay Dearden, Annette Lam
Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)-based treatments, and to explore differences in patient outcomes...
November 8, 2018: Leukemia & Lymphoma
Arielle van Mourik, Andrew Grigg
No abstract text is available yet for this article.
November 8, 2018: Leukemia & Lymphoma
Olga Zajac-Spychala, Jacek Wachowiak, Anna Szmydki-Baran, Lukasz Hutnik, Malgorzata Salamonowicz, Michal Matysiak, Krzysztof Czyzewski, Mariusz Wysocki, Patrycja Zalas-Wiecek, Zofia Malas, Wanda Badowska, Olga Gryniewicz-Kwiatkowska, Aneta Czajnska-Deptuła, Elwira Kulicka, Bozenna Dembowska-Baginska, Danuta Perek, Katarzyna Semczuk, Katarzyna Dzierzanowska-Fangrat, Tomasz Ociepa, Magdalena Bartnik, Liliana Chelmecka-Wiktorczyk, Walentyna Balwierz, Joanna Klepacka, Nina Irga-Jaworska, Ewa Bien, Elzbieta Adamkiewicz-Drozynska, Agnieszka Urbanek-Dadela, Grazyna Karolczyk, Filip Pierlejewski, Wojciech Mlynarski, Marcin Plonowski, Maryna Krawczuk-Rybak, Weronika Stolpa, Grazyna Sobol, Renata Tomaszewska, Tomasz Szczepanski, Zuzanna Gamrot, Mariola Woszczyk, Maria Wieczorek, Jerzy Kowalczyk, Jan Styczynski
The objective of this nation-wide study was to evaluate the epidemiology and profile of bacterial (BI), viral (VI), and invasive fungal disease (IFD) in patients treated for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) between the years 2013-2015. In the analyzed period of time, within the studied group of 328 children diagnosed and treated for lymphomas, at least one infectious complication (IC) was diagnosed i.e. 39.3% children. In these patients there were 350 episodes of IC, therein 80.6% episodes of BI, 11...
November 5, 2018: Leukemia & Lymphoma
Jason Tay, Ravi Vij, Maxim Norkin, Francis Buadi, Tamila L Kindwall-Keller, Jenna S Roberts, Darrell J White, Robert P Wood, Sophee E Blanthorn-Hazell, Adriana C Rossi, Sujith Dhanasiri, Faiza Zafar, Kim Newhouse, Arleigh R McCurdy
Maintenance (MT) may be prescribed after autologous stem cell transplant (ASCT) but there are often concerns about the impact on quality of life (QoL). QoL was compared between baseline patients (30-100 days post-ASCT and had not commenced MT); MT patients (>100 days post-ASCT and receiving MT), and no MT (>100 days post-ASCT and not receiving MT). Patients completed the EuroQoL five dimension (EQ-5D), the European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30), and the QoL Questionnaire Myeloma 20 module (QLQ-MY20)...
October 31, 2018: Leukemia & Lymphoma
Henning D Popp, Johanna Flach, Susanne Brendel, Sabrina Ruppenthal, Helga Kleiner, Wolfgang Seifarth, Sven Schneider, Torsten J Schulze, Christel Weiss, Frederik Wenz, Wolf-Karsten Hofmann, Alice Fabarius
Accumulation of DNA damage and alteration of the DNA damage response (DDR) are critical features of genetic instability that is presumed to be implicated in the pathogenesis of monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Here, we show increased numbers of γH2AX foci, a marker of DNA double-strand breaks (DSB), in CD19+ cells of CLL patients as compared to CD19+ cells of MBL patients and healthy individuals. Furthermore, numerous γH2AX/53BP1 foci in CLL cells suggest activation of error-prone non-homologous end-joining repair mechanisms...
October 31, 2018: Leukemia & Lymphoma
Jerry Soff, James Bussel
No abstract text is available yet for this article.
October 18, 2018: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"